CG Oncology bladder cancer immunotherapy cuts recurrence risk by 68%
Published 2 d ago1 sourceEvidence: Reported
Sellas Life Sciences reported that its experimental immunotherapy for a blood cancer reduced the risk of death in a clinical trial. The specific cancer type, effect size, and statistical significance are not detailed in the source. This is a company-specific clinical development with potential implications for the company's pipeline and the broader oncology landscape, but no market-moving macro impact is indicated.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Published 2 d ago1 sourceEvidence: Reported
Published 1 d ago2 sourcesEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 5 h ago1 sourceEvidence: Reported
Published 18 h ago1 sourceEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported